Intensity Therapeutics, Inc. Common stock (INTS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Intensity Therapeutics, Inc. Common stock (INTS) has a cash flow conversion efficiency ratio of -0.183x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.83 Million) by net assets ($9.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See INTS cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Intensity Therapeutics, Inc. Common stock - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Intensity Therapeutics, Inc. Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Intensity Therapeutics, Inc. Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Intensity Therapeutics, Inc. Common stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Synertec Corporation Ltd
AU:SOP
|
0.100x |
|
Cellectar Biosciences Inc
NASDAQ:CLRB
|
-0.438x |
|
HiteJinro Co Ltd
KO:000087
|
-0.015x |
|
Surgepays Inc
NASDAQ:SURG
|
0.723x |
|
Euroland Corporate SA
PA:MLERO
|
N/A |
|
MILA RESOUR. PLC LS-01
F:HN0
|
N/A |
|
Medadvisor Ltd
AU:MDR
|
5.093x |
|
TWZ Corporation Public Company Limited
BK:TWZ
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Intensity Therapeutics, Inc. Common stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Intensity Therapeutics, Inc. Common stock from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Intensity Therapeutics, Inc. Common stoc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $11.88 Million | $-9.23 Million | -0.777x | +85.09% |
| 2024-12-31 | $2.92 Million | $-15.22 Million | -5.216x | -852.83% |
| 2023-12-31 | $13.16 Million | $-7.21 Million | -0.547x | -250.89% |
| 2022-12-31 | $-15.10 Million | $-5.48 Million | 0.363x | -53.85% |
| 2021-12-31 | $-8.68 Million | $-6.83 Million | 0.786x | -77.19% |
| 2020-12-31 | $-1.56 Million | $-5.37 Million | 3.446x | +700.77% |
| 2019-12-31 | $7.70 Million | $-4.42 Million | -0.574x | -- |
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is… Read more